Riskpilot← Back to searchSign inGet full accessNexos Biosciences AB
ABActiveOrg 5594232224Erik Dahlbergsgatan 11 A 2 VånManufacture of pharmaceutical preparations · NACE 2120Est. 20230 employees
Revenue 2024
SEK 0
EBITDA margin
—
-9% vs 2023
Equity ratio
98.5%
Financial strength
Net profit 2024
SEK -272K
-2% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -302K | -9% |
| Net profit | SEK -272K | -2% |
| Total assets | SEK 879K | -23% |
| Equity | SEK 866K | -24% |
| Employees | 0 | — |
Legal name
Nexos Biosciences AB
Org number
5594232224
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
22 februari 2023
Share capital
SEK 51 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av en av ledamöterna i förening med suppleanterna
Company purpose
Bolaget skall bedriva utveckling syftande till kommersiell exploatering av nya behandlingsmetoder inom medicin, bland annat immunologi-området och därmed förenlig verksamhet.
Address
Erik Dahlbergsgatan 11 A 2 Vån
Email
magnus.kall@ventures.gu.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Staff expenses | — | — |
| EBITDA | −277 | −302 |
| Depreciation & amort. | −0 | −0 |
| EBIT | −277 | −302 |
| Net financials | 10 | 30 |
| Profit before tax | −267 | −272 |
| Tax | −0 | −0 |
| Net profit | −267 | −272 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 1 148 | 879 |
| Equity | 1 138 | 866 |
| Long-term debt | 0 | 0 |
| Short-term debt | 10 | 13 |
| Total debt | 10 | 13 |
EBITDA margin
-30200000.0%
This company
15.8%
Market median
-191139341% vs market
20232024
Equity ratio
98.5%
This company
38.2%
Market median
+158% vs market
20232024
Return on equity
-31.4%
This company
18.4%
Market median
-271% vs market
20232024
Net profit margin
-27200000.0%
This company
8.1%
Market median
-335802569% vs market
20232024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20232024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20232024
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Deputy Board Member | 2023 | |
| Deputy Board Member | 2023 | |
| Board of Directors | 2023 | |
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 51% | 51% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Jan Lötvall Holding AB
Nexos Biosciences AB Board members of Nexos Biosciences AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kyongsu Park | Deputy Board Member | 0 companies |
| Per Jesper Dahlberg | Deputy Board Member | 0 companies |
| Jan Olof Lötvall | Board of Directors | 0 companies |
| Bengt Anders Waas | Board of Directors | 0 companies |
| Mats Göte Uno Persson | Chairman | 0 companies |